%PDF-1.4
%
36 0 obj
<>
endobj
33 0 obj
<>
endobj
188 0 obj
<>stream
Acrobat Distiller 4.05 for Macintosh
2004-12-02T16:50:07Z
2024-03-29T06:01:57-07:00
QuarkXPressª: AdobePS 8.6 (219)
2024-03-29T06:01:57-07:00
application/pdf
Heather
201317.dec
uuid:19c5feab-1dd2-11b2-0a00-8909271d5700
uuid:19c5feae-1dd2-11b2-0a00-bf0000000000
endstream
endobj
22 0 obj
<>
endobj
23 0 obj
<>
endobj
37 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
1 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
4 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
7 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Type/Page>>
endobj
15 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
210 0 obj
[215 0 R]
endobj
211 0 obj
<>stream
1 g
/GS0 gs
0 792 m
0 792 l
f
q
-1 793 614 -794 re
W n
q
0 792.06 612 -792 re
W n
/CS0 cs 0 0 0 0 scn
/GS1 gs
465 777 92 -27 re
f*
/CS0 CS 0 0 0 1 SCN
54 54 m
558 54 l
S
BT
0 0 0 1 scn
/TT0 1 Tf
0.02499 Tw 8 0 0 8 420.3613 35.9844 Tm
(The Journal of Rheumatology 2001; 28:12)Tj
0 Tw -45.7952 -0.0313 Td
(2704)Tj
ET
0 0 0 0 scn
/GS0 gs
103.25 56.03 407.5 -10.83 re
f*
Q
Q
q
1 0 0 1 0 3 cm
-1 793 614 -794 re
W n
q
0 792.06 612 -792 re
W n
/CS0 CS 0 0 0 1 SCN
0.5 w
103.25 56.03 407.5 -10.83 re
S
Q
Q
q
-1 793 614 -794 re
W n
q
0 792.06 612 -792 re
W n
BT
/CS0 cs 0 0 0 1 scn
/GS1 gs
/TT1 1 Tf
0.15491 Tw 10 0 0 10 54 713.1616 Tm
[(ation in RA, where the binary )55 (ACR20 endpoint has been)]TJ
0.1562 Tw 0 -1.2 TD
(shown to be similarly precise to the best from among its)Tj
0 Tw T*
(components)Tj
6.5 0 0 6.5 102.3227 692.4615 Tm
(1)Tj
0.0538 Tw 10 0 0 10 105.5727 689.1616 Tm
[(, and a continuous composite of the )55 (ACR core)]TJ
0.0033 Tw -5.1573 -1.2 Td
(set of endpoints has been shown to be more precise than the)Tj
0.1515 Tw T*
(individual components for discriminating active treatment)Tj
0.1637 Tw T*
(from placebo)Tj
0 Tw 6.5 0 0 6.5 108.6645 656.4615 Tm
(4)Tj
0.1459 Tw 10 0 0 10 111.9145 653.1616 Tm
[(. T)35 (illey)65 (, )]TJ
/TT0 1 Tf
0.1637 Tw 3.5979 0 Td
(et al)Tj
/TT1 1 Tf
0 Tw 6.5 0 0 6.5 167.0261 656.4615 Tm
(3)Tj
0.1637 Tw 10 0 0 10 174.4133 653.1616 Tm
(have shown that correlations)Tj
0.0007 Tw -12.0413 -1.2 Td
[(among components of the )55 (ACR20, while statistically signif-)]TJ
0 Tw T*
[(icantly positive, are of moderate magnitude. )18 (Their estimates)]TJ
0.1506 Tw T*
[(of correlation coef)18 (ficients among the RA)-346 (endpoints range)]TJ
0.0574 Tw T*
[(from 0.13 to 0.73, with most in the 0.2 to 0.6 range. )18 (These)]TJ
0.0807 Tw T*
[(contrast to those found among OA)-276 (endpoints in this paper)55 (.)]TJ
0.07851 Tw T*
(This could be part of the explanation for not having found)Tj
0.1237 Tw T*
[(an OA)-319 (composite endpoint with substantially better sensi-)]TJ
0.02499 Tw T*
(tivity than its individual components.)Tj
0.2121 Tw 1.2 -1.2 Td
[(The correlation, principal components, and ef)18 (fect size)]TJ
0.0538 Tw -1.2 -1.2 Td
(analyses were also carried out on the change from baseline)Tj
0.263 Tw T*
(to the last on-treatment observation, and yielded results)Tj
-0.0323 Tw T*
(\(data not shown\) similar to those of the average change from)Tj
0.1084 Tw T*
(baseline. In addition, the correlation and principal compo-)Tj
0.0601 Tw T*
(nent analyses were carried out on the average change from)Tj
0.101 Tw T*
[(baseline after removal of the treatment ef)18 (fect by assessing)]TJ
-0.00011 Tc 0.2422 Tw T*
[(residuals from analysis of variance. )18 (These analyses also)]TJ
0 Tc 0.22791 Tw T*
(yielded qualitatively similar results, although the magni-)Tj
0.00079 Tc 0.3741 Tw T*
[(tudes of the correlation coef)18 (ficients were slightly less)]TJ
0.02 Tc 0.6106 Tw T*
(because correlated treatment-induced changes were)Tj
0 Tc 0.28551 Tw T*
[(removed from the data. )18 (Thus, these additional analyses)]TJ
-0.00011 Tc 0.11909 Tw T*
(demonstrated the robustness of the results reported in this)Tj
0 Tw T*
[(paper)55 (.)]TJ
0 Tc 0.0331 Tw 1.2 -1.2 Td
(Several additional potential interpretations can be drawn)Tj
-0.00011 Tc -0.03529 Tw -1.2 -1.2 Td
[(from careful examination of trends in the results from )18 (T)70 (ables)]TJ
0 Tc -0.0103 Tw T*
[(1 and 3 and Figure 1. First, not all correlation coef)18 (ficients in)]TJ
0.0965 Tw T*
[(T)70 (able 1 are lar)18 (ge \(> 0.7\), suggesting that each of the indi-)]TJ
0.0923 Tw T*
(vidual endpoints does provide some degree of information)Tj
-0.0006 Tw T*
[(independent of the others. However)40 (, that degree appears not)]TJ
0.01871 Tw T*
(to be great enough to have a marked influence on the preci-)Tj
0.2019 Tw T*
(sion of composite endpoints in relation to the individual)Tj
0.015 Tw T*
[(endpoints. Second, from )18 (T)70 (able 3, the 2 individual endpoints)]TJ
0.0006 Tc 0.3744 Tw T*
[(that have ef)18 (fect sizes rivaling those of the composite)]TJ
0 Tc 0.21609 Tw T*
(endpoints are both the global evaluations of response to)Tj
-0.02409 Tw T*
[(therapy)65 (, the use of which tends to be limited to trials of short)]TJ
0.10091 Tw T*
[(duration since they depend on patients\222)-277 (recall of compara-)]TJ
-0.00011 Tc 0.2551 Tw T*
[(tive response versus baseline. )55 (All except one composite)]TJ
0 Tc 0.3643 Tw T*
[(endpoint show ef)18 (fect sizes in excess of all individual)]TJ
0.2749 Tw T*
(endpoints except for the response to therapy endpoints;)Tj
0.21429 Tw T*
[(however)40 (, as shown in Figure 1, the confidence intervals)]TJ
0.02499 Tw T*
[(overlap substantially)65 (.)]TJ
-0.00011 Tc 0.1555 Tw 1.2 -1.2 Td
[(Third, it is surprising that ef)18 (fect sizes of all )18 (WOMAC)]TJ
0 Tc 0.11189 Tw -1.2 -1.2 Td
(endpoints tend to be lower than patient global evaluations)Tj
0.1237 Tw T*
(and other composite endpoints. In addition, the individual)Tj
0.09489 Tw T*
[(WOMAC endpoint Pain )18 (W)80 (alking on a Flat Surface has an)]TJ
0.3109 Tw T*
[(ef)18 (fect size similar to those of the individual )18 (WOMAC)]TJ
0.19991 Tw 26.4 60 Td
[(subscales and the Overall )18 (WOMAC score; however)40 (, this)]TJ
0.0677 Tw T*
(could, at least in part, be accounted for by the requirement)Tj
0.0676 Tw T*
[(of at least a 15 mm worsening at baseline of Pain )18 (W)80 (alking)]TJ
-0.00011 Tc 0.00549 Tw T*
[(on a Flat Surface during prior OA)-201 (therapy washout. )18 (These 3)]TJ
0 Tc 0.1996 Tw T*
(trends should be viewed as hypothesis generating, rather)Tj
0.01469 Tw T*
(than conclusive, since they are based on subtle trends in the)Tj
0.02499 Tw T*
[(data rather than on marked dif)18 (ferences that exceed limits of)]TJ
0.2912 Tw T*
(variability of the estimates. Hence, they require further)Tj
-0.00011 Tc 0.02499 Tw T*
(study to establish or refute.)Tj
0 Tc 0.1024 Tw 1.2 -1.2 Td
(In conclusion, analyses of data from 2 separate 6 week)Tj
0.0013 Tc 0.3737 Tw -1.2 -1.2 Td
(placebo controlled, flare designed study protocols that)Tj
-0.00011 Tc 0.1353 Tw T*
[(showed the ef)18 (ficacy of the COX-2-specific inhibitor rofe-)]TJ
0 Tc 0.1451 Tw T*
[(coxib in patients with hip or knee OA)-340 (revealed that indi-)]TJ
0.02 Tc 0.9101 Tw T*
(vidual study endpoints were highly correlated.)Tj
0 Tc 0.2941 Tw T*
[(Consequently)65 (, composite endpoints did not increase the)]TJ
0.0237 Tw T*
[(precision of ef)18 (ficacy comparisons beyond that of individual)]TJ
0.00079 Tw T*
[(endpoints. )55 (Although composites were not shown to increase)]TJ
0.0118 Tw T*
[(precision, they may be useful in OA)-207 (to address other issues,)]TJ
0.231 Tw T*
(for example, multiplicity of endpoints and estimation of)Tj
0.02499 Tw T*
(overall level of response.)Tj
/TT2 1 Tf
-0.00011 Tc 0 Tw 0 -2.4 TD
(ACKNOWLEDGMENT)Tj
/TT1 1 Tf
0 Tc 0.093 Tw 8 0 0 8 318 451.1616 Tm
(The authors thank the reviewers for their careful and thoughtful reviews\
.)Tj
0.0452 Tw 0 -1.25 TD
(Their questions and suggestions led to addition of valuable information \
to)Tj
0.02499 Tw T*
(this manuscript.)Tj
/TT2 1 Tf
-0.00011 Tc 0 Tw 10 0 0 10 318 407.1616 Tm
(REFERENCES)Tj
/TT1 1 Tf
0.02499 Tw 8 0 0 8 325 397.1616 Tm
[(1.)-875 (Felson D, )55 (Anderson JJ, Boers M, et al. )55 (American College of)]TJ
0 Tc 1.675 -1.25 Td
(Rheumatology preliminary definition of improvement in)Tj
T*
[(rheumatoid arthritis. )55 (Arthritis Rheum 1995;38:727-35.)]TJ
-1.675 -1.25 Td
[(2.)-875 (Buchbinder R, Bombardier C, )37 (Y)100 (eung M, )18 (T)35 (ugwell P)111 (. )18 (Which outcome)]TJ
1.675 -1.25 Td
(measures should be used in rheumatoid arthritis clinical trials?)Tj
T*
(Arthritis Rheum 1995;38:1568-80.)Tj
-0.00011 Tc -1.675 -1.25 Td
[(3.)-875 (T)35 (illey BC, Pillemer SR, Heyse SP)111 (, et al. Global statistical tests for)]TJ
0 Tc 1.675 -1.25 Td
[(comparing multiple outcomes in rheumatoid arthritis trials. )55 (Arthritis)]TJ
T*
(Rheum 1999;42:1879-88.)Tj
-1.675 -1.25 Td
[(4.)-875 (Zeng Q, Bolognese J, Ehrich E, Daniels B. Comparison of several)]TJ
-0.00011 Tc 1.675 -1.25 Td
[(composite endpoints in the assessment of MK-0966 ef)18 (ficacy in)]TJ
T*
[(rheumatoid arthritis [abstract]. )55 (Arthritis Rheum 1998;41 Suppl)]TJ
0 Tc 0 Tw T*
(9:S207.)Tj
-0.00011 Tc 0.02499 Tw -1.675 -1.25 Td
[(5.)-875 (O\222Brien PC. Procedures for comparing samples with multiple)]TJ
0 Tc 1.675 -1.25 Td
(endpoints. Biometrics 1984;40:1079-87.)Tj
-1.675 -1.25 Td
[(6.)-875 (Ehrich E, Schnitzer )18 (T)74 (, Kivitz )55 (A, et al. MK-966, a highly selective)]TJ
1.675 -1.25 Td
[(Cox-2 inhibitor)40 (, was ef)18 (fective in the treatment of osteoarthritis of)]TJ
T*
(the knee and hip in a 6-week placebo controlled study [abstract].)Tj
T*
(Arthritis Rheum 1997;40 Suppl 9:S85.)Tj
-0.00011 Tc -1.675 -1.25 Td
[(7.)-875 (Saag K, Fisher C, McKay J, et al. MK-0966, a specific Cox-2)]TJ
0 Tc 1.675 -1.25 Td
[(inhibitor)40 (, has clinical ef)18 (ficacy comparable to ibuprofen in the)]TJ
T*
(treatment of knee and hip osteoarthritis in a 6-week controlled)Tj
T*
[(clinical trial [abstract]. )55 (Arthritis Rheum 1998;41 Suppl 9:S196.)]TJ
-1.675 -1.25 Td
[(8.)-875 (Day R, Morrison BW)92 (, Luza )55 (A, et al. )55 (A)-220 (randomized trial of the)]TJ
1.675 -1.25 Td
[(ef)18 (ficacy and tolerability of the COX-2 inhibitor rofecoxib vs)]TJ
T*
[(ibuprofen in patients with osteoarthritis. )55 (Arch Intern Med)]TJ
0 Tw T*
(2000;160:1781-7.)Tj
0.0249 Tw -1.675 -1.25 Td
[(9.)-875 (Morrison DF)80 (. Multivariate statistical methods. New )37 (Y)100 (ork: McGraw-)]TJ
1.675 -1.25 Td
(Hill; 1967:222-7.)Tj
ET
Q
Q
q
0 0 612 792 re
W n
BT
0 g
ET
/GS2 gs
BT
/T1_0 8 Tf
120.092 51 Td
(Personal non-commercial use only. The Journal of Rheumatology Copyright\
\251 2001. All rights reserved.)Tj
ET
Q
BT
0 g
/GS3 gs
/T1_1 1 Tf
10 0 0 10 540 17 Tm
( )Tj
0 0.48627 0.77255 rg
/GS3 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS3 gs
-16.72996 0 Td
(Downloaded on March 29, 2024 from )Tj
ET
endstream
endobj
75 0 obj
<>
endobj
194 0 obj
<>
endobj
39 0 obj
<>
endobj
44 0 obj
<>
endobj
18 0 obj
<>
endobj
19 0 obj
<>
endobj
20 0 obj
<>stream
HdVpTs͋ ,1$^Z$@.4Hy1 VvÀF" 錈h
*
ZHa"^3ZIԊұ4U5uoswA?_}`(V+{ڏQ:5w
Ɔe/~go;|@w-MƝg>|>;WPdڱ|qAi̸yIC>5-3om:*`B-)j[L(mK}?>3[-'
y{8wZHq4Z0 >eX1˰v#,Q!W<e*RɵhF7>jVD|"EnUX.vZ5=zOoKpInrۋBqv\ncD3\CXFZ|Ot0J1qm^f/y&7< gs*ha<}CBJdt7K}(܉_aEWJPMPK.Ɩ]haĔ\NOO@F2TͼjeIt'z\ӝuS
Y70%̡ߏuHDz|s<{K:BzdUe'}c0,8Iy^G+*0yZilmr;ilGY'e;'9{#f}F0UB@ݡVV8!%Ec467fj>g`Z3Ӻz:fL֝.}cIvO.'1-j &.*Y&u'W[YU~-V3 ycݪޜ㨔Cadn|)`s1w8ͳAFtLh`Ty#}#_4,r?oȟ448jWΘcg >HsUc\5JjjJ*Q~N-5y5㇒?kN岖h,BsBlFVEFCaⷷhgGH;Ex3{Nm4rq P,vdZ};?6~Oչ,^Fqni.~]c>.댰#Έ_~~;Et訢xSW%KzFrӻUӬZUWȪd^,쨖L;lt-[;/:kw6S,ʁ:%[\}WRCd~/
8~TlgcΘ&--W dEk֠lD^=>土#(ϮI{F+55T3k$.K+B9vwxų?.o)}m3:P+헲qGsꅉ+ioqmHM)yItcոدczniwQ_=#şE/so֒w'zNjڬ;0Lϴ7zv{D=R=֧ջۯ|Eqqy{ٽx}8;p<Р, hS%AE!1DE`:
c:qӖf-,13)h&M6NCiEej:cݙy}<{nlt\9pj jD y0K# kd/= ^#8X5 hdI# FvBВ|],Gh6>R!
`EKd=`?;:i{n
naI3Bu5%*R6$1ꖓm66LMxM(n*]p\M
%J!P$jW6M^ƣQᥨDP=psݯݶvn%:eg~p2Wx1Wha|..'9#Bƈ0* NT6`f>I5&
]>ScAj,D+(C~G( ̬;JoV} }U:o_ңwT)pM oxK2 U%𦪄 Te༪D T85jx@Ux ߫ƒ5حƊjZO};fְ'm@OoA}Iܪ7#nsγ_3q*UCzUJ>`^}UHg)zG ȖqרkfT'A?T"3O#<<9$O%~A!琥J~UZT9t{Te6XDa_(